Showing results (31-40 of 46) with videos related to
Sort By:
Pageof 5
The American Journal of Psychiatry|June 1, 1993
Depression and neuropsychological performance in asymptomatic HIV infectionR A Bornstein, P Pace, P Rosenberger, et al.The Journal of Infectious Diseases|July 7, 2000
Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333A D Sevin, V DeGruttola, M Nijhuis, et al.The Journal of Neuropsychiatry and Clinical Neurosciences|January 1, 1993
Drug and alcohol use and neuropsychological performance in asymptomatic HIV infectionR A Bornstein, R Fama, P Rosenberger, et al.The Journal of Neuropsychiatry and Clinical Neurosciences|January 11, 1992
Neuropsychological performance in asymptomatic HIV infectionR A Bornstein, H A Nasrallah, M F Para, et al.Comprehensive Psychiatry|May 1, 1993
Psychopathology in human immunodeficiency virus infection: lifetime and current assessmentP H Rosenberger, R A Bornstein, H A Nasrallah, et al.Journal of Clinical and Experimental Neuropsychology|October 1, 1994
Neuropsychological performance and CD4 levels in HIV-1 asymptomatic infectionA M Podraza, R A Bornstein, C C Whitacre, et al.Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|May 1, 1997
Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151M A Fischl, D D Richman, C Flexner, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 24, 2001
Qualitative and quantitative PCR measures of cytomegalovirus in patients with advanced HIV infection who require transfusionsM F Para, L A Kalish, A C Collier, et al.Antimicrobial Agents and Chemotherapy|March 1, 1994
Foscarnet for suppression of human immunodeficiency virus replicationC V Fletcher, A C Collier, F S Rhame, et al.Antimicrobial Agents and Chemotherapy|February 19, 2000
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)L M Demeter, R W Shafer, P M Meehan, et al.Pageof 5